Angiotensin Receptor-Neprilysin Inhibitor

LCZ 696 for Type 2 Diabetes

Phase 2
Led By Horng H Chen
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
Be younger than 18 years old
Screening 3 weeks
Treatment Varies
Follow Up3months
Awards & highlights
All Individual Drugs Already Approved
Approved for 10 Other Conditions

Study Summary

This trial will help researchers learn more about how diabetes affects heart function and whether a new treatment can prevent heart failure in people with diabetes.

Eligible Conditions
  • Type 2 Diabetes
  • Diastolic Dysfunction


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Plasma cGMP Response
Secondary outcome measures
Renal response

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: LCZ 696Active Control2 Interventions
1st Experimental Arm will be 1 capsule of LCZ 696 given orally, one time
Group II: PlacebosPlacebo Group1 Intervention
Control Intervention will be 1 Placebo Capsule given orally, one time

Find a site

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,077 Previous Clinical Trials
3,490,942 Total Patients Enrolled
Horng H ChenPrincipal Investigator
Mayo Clinic

Media Library

LCZ 696 (Angiotensin Receptor-Neprilysin Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT03744975 — Phase 2
Type 2 Diabetes Research Study Groups: LCZ 696, Placebos
Type 2 Diabetes Clinical Trial 2023: LCZ 696 Highlights & Side Effects. Trial Name: NCT03744975 — Phase 2
LCZ 696 (Angiotensin Receptor-Neprilysin Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03744975 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can older people participate in this research?

"This study is open to participants aged 18-85."

Answered by AI

Do people exhibit negative side effects from LCZ 696?

"LCZ 696's safety is based off of preclinical data and was given a score of 2."

Answered by AI

Which type of person is this research looking for?

"This clinical study is looking for 72 males and females, aged 18 to 85, that have type 2 diabetes mellitus. In addition to this broad inclusion criteria, participants must also meet the following specific conditions: EF > 50% without diastolic dysfunction or EF > 50% with grade 2 or more diastolic dysfunction, without prior diagnosis, or signs and symptoms, of heart failure, 60 male and female subjects >18years of age, Type 2 diabetes mellitus, On at least one oral hypoglycemic agent, or glucagon-like peptide analogue or insulin, for at least 6 months, Minimal distance of >450"

Answered by AI

Are participants currently being recruited for this research?

"No, this particular clinical trial is not presently recruiting patients. However, according to the data hosted on, it was last edited on 8/18/2022. There are many other clinical trials (874 in total) that are actively looking for patients right now."

Answered by AI

How many people are included in the experimental group for this clinical trial?

"This study has completed recruitment for participants. However, if you're looking for other research opportunities, 835 clinical trials are currently underway that focus on diabetes mellitus, type 2 and 39 studies are investigating the efficacy of LCZ 696."

Answered by AI

Can you give us some background on other similar research projects to LCZ 696?

"There are currently 8 Phase 3 trials and 39 total studies being conducted for LCZ 696. The majority of these research sites are located in Montreal, but there are a grand total of 812 locations running clinical trials for LCZ 696."

Answered by AI

What are LCZ 696's primary therapeutic benefits?

"Patients with uncontrolled hypertension and Ventricular Dysfunction can find relief with LCZ 696."

Answered by AI
~10 spots leftby Jun 2024